Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial
City of Hope · Beckman Research Institute · +3 more institutions
Abstract
Abstract Chimeric antigen receptor T cell (CAR-T) therapy is an emerging strategy to improve treatment outcomes for recurrent high-grade glioma, a cancer that responds poorly to current therapies. Here we report a completed phase I trial evaluating IL-13Rα2-targeted CAR-T cells in 65 patients with recurrent high-grade glioma, the majority being recurrent glioblastoma (rGBM). Primary objectives were safety and feasibility, maximum tolerated dose/maximum feasible dose and a recommended phase 2 dose plan. Secondary objectives included overall survival, disease response, cytokine dynamics and tumor immune contexture biomarkers. This trial evolved to evaluate three routes of locoregional T cell administration…
Citation impact
- FWCI
- 69.44
- Percentile
- 100%
- References
- 78
Authors
30- CEChristine E. BrownCorresponding
City of Hope
- JHJonathan Hibbard
City of Hope, Beckman Research Institute
- DADarya Alizadeh
City of Hope, Beckman Research Institute
- MSM. Suzette Blanchard
City Of Hope National Medical Center, City of Hope, Beckman Research Institute
- HMHeini M. Natri
Translational Genomics Research Institute
Topics & keywords
- Medicine
- Glioma
- Chimeric antigen receptor
- Oncology
- Internal medicine
- Immunotherapy
- Cancer
- Cancer research
- Good health and well-being
Funding
- CICalifornia Institute for Regenerative MedicineAwards: TR3-05641, CLIN2-12153, CLIN2-10248
- GFGateway for Cancer ResearchAward: G-14-600
- COCity of Hope
- NINational Institutes of HealthAwards: P30CA033572, R01CA236500, R21NS081594, R21CA189223, K12CA001727, CLIN2-10248, R01CA155769
- UFU.S. Food and Drug AdministrationAward: R01FD005129
- NCNational Cancer InstituteAwards: K12CA001727, R01CA236500, R01CA155769, P30CA033572, R21CA189223